HC Wainwright Reaffirms “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $46.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 175.45% from the company’s current price.

A number of other analysts have also recently commented on the stock. JPMorgan Chase & Co. cut their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Wells Fargo & Company began coverage on iTeos Therapeutics in a research note on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price for the company. Finally, Wedbush reissued an “outperform” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a research note on Thursday, August 8th.

iTeos Therapeutics Price Performance

iTeos Therapeutics stock opened at $16.70 on Monday. The stock’s 50 day moving average is $16.30 and its 200 day moving average is $14.64. iTeos Therapeutics has a one year low of $8.20 and a one year high of $18.75. The firm has a market cap of $603.25 million, a P/E ratio of -4.42 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.86. The firm had revenue of $35.00 million during the quarter, compared to analyst estimates of $4.20 million. Equities analysts anticipate that iTeos Therapeutics will post -4.21 earnings per share for the current fiscal year.

Institutional Trading of iTeos Therapeutics

Several large investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its stake in iTeos Therapeutics by 6.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock worth $164,000 after buying an additional 690 shares during the period. Public Employees Retirement System of Ohio raised its position in shares of iTeos Therapeutics by 4.9% during the first quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock worth $532,000 after purchasing an additional 1,817 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of iTeos Therapeutics by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,877 shares of the company’s stock worth $94,000 after purchasing an additional 2,737 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in iTeos Therapeutics by 35.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock valued at $178,000 after purchasing an additional 3,172 shares during the period. Finally, Rhumbline Advisers increased its stake in iTeos Therapeutics by 8.5% during the 2nd quarter. Rhumbline Advisers now owns 44,861 shares of the company’s stock valued at $666,000 after purchasing an additional 3,513 shares in the last quarter. 97.16% of the stock is currently owned by institutional investors and hedge funds.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.